---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-149353"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2023-05-19T23:59:59+00:00"
generated_at: "2026-06-14T19:53:37.271862+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Magenta Therapeutics CSO Dr. Lisa Olson departs effective May 15, 2023 amid proposed merger with Dianthus

## Summary
- Dr. Lisa Olson, Head of Research and CSO, left Magenta on May 15, 2023 due to completion of certain asset sales and announced proposed merger with Dianthus.
- Magenta entered into a consulting agreement with Dr. Olson for work on an as-requested basis at an hourly rate.
- Dr. Olson is eligible for severance benefits under her amended employment agreement, subject to execution of a separation agreement.
- The departure is part of restructuring related to the proposed merger with Dianthus Therapeutics.

## SEC filing metadata
- accession: 0001193125-23-149353
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2023-05-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000119312523149353/0001193125-23-149353-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000119312523149353/d469753d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-149353
- JSON: https://secwatch.observer/filing/0001193125-23-149353.json
- Plain text: https://secwatch.observer/filing/0001193125-23-149353.txt

## Key facts
- Executive change
  Dr. Lisa Olson departed as Head of Research and Chief Scientific Officer at Dianthus Therapeutics, Inc. /DE/.
  - Action: left
  - Role: Head of Research and Chief Scientific Officer
  source text: Effective May 15, 2023, Dr. Lisa Olson, Head of Research and Chief Scientific Officer of Magenta Therapeutics, Inc. (the “Company” or “Magenta”), has left the Company due to the completion of the sale of certain of Magenta’s assets and its announced proposed merger with Dianthus Therapeutics, Inc. (“Dianthus”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000119312523149353/0001193125-23-149353-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.